Merck + Co., Inc.

Ucbbiopharma Srl

Merck Sharp + Dohme Corp.

Sanofi

Ucb Biopharma Sprl

Cardurion Pharmaceuticals, LLC

Other

Southern Research Institute

Ptc Therapeutics, Inc.

Isis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Ann E. Weber

Scott D. Edmondson

Jinyou Xu

Dooseop Kim

Malcolm Maccoss

Sander G Mills

Paul E Finke

Zhaoning Zhu

William K Hagmann

Shrenik K Shah

Ann E Weber

Scott D Edmondson

Emma R Parmee

Charles G Caldwell

Phillip Dan Cook

F George Njoroge

Thazha P Prakash

Balkrishen Bhat

Philippe L Durette

Michael H Fisher

Daniel Christopher Brookings

David Brian Olsen

William J Greenlee

Ronald J Doll

Joseph A Kozlowski

Timothy Harrison

Anandan Palani

Gary Mitchell Karp

Timothy J Guzi

Volkmar Wehner

Duane A Burnett

William F Hoffman

Frank W Bennett

Hubert B Josien

Brian John Williams

Wolfgang J Wrasidlo

Xianhai Huang

Ashok Arasappan

Stephane L Bogen

Conrad P Dorn

Dong-Ming Shen

Uwe Heinelt

Jeffrey John Hale

Mark Stewart Chambers

Rikki Peter Alexander

Srikanth Venkatraman

John A Secrist, Iii

Guangming Chen

Ling Tong

Bandarpalle B Shankar

Matthew Ernst Voss

Manami Shizuka

Yuan Liu

Gabor Butora

Kevin Tyler Chapman

Richard David Taylor

Ravindra N Guthikonda

Junya Shirai

James Andrew Johnson

Martin Clive Hutchings

Marija Prhavc

Tomohiro Okawa

Jag Paul Heer

Anne Bettina Eldrup

Yasufumi Miyamoto

Quanlai Song

Akito Shibuya

Tamara Ladduwahetty

Laurent Schio

Subramaniam Ananthan

Julien Alistair Brown

Boris Kroeplien

Xiaoyan Zhang

Hongmei Li

Vinay M Girijavallabhan

Victoria Elizabeth Jackson

Haoyun An

Emily M Stocking

Seong Heon Kim

Craig R Gibeau

Nanjing Zhang

Charles John Guinosso

Richard A Mumford

Zhong-Yue Sun

Steven David Paget

Francisco Velazquez

Yaolin Wang

Latha G Nair

Matthew Duncan Selby

Liping Wang

Bruno Filoche-Romme

Hongyu Ren

William Jospeh Lennox

Weidong Pan

Joseph A Maddry

Laurent Provins

Feng Geng

Vishal Verma

Ruo Xu

Yuhua Huang

Chad E Bennett

Xiaoxiang Liu

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Fused pentacyclic imidazole derivatives

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description,or a pharmaceutically acceptable salt thereof.

Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors

The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of theparasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria. 

Antimalarial hexahydropyrimidine analogues

A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Aminopyrimidine compound

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation

Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R, R, and Rare defined herein. These compounds are potent modulators of human TNF&#x3b1; activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused pentacyclic imidazole derivatives as modulators of TNF activity

Bis-heteroaryl derivatives as modulators of protein aggregation

The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma. 

Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation

A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria. 

Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors

A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused tricyclic imidazole derivatives as modulators of TNF activity

The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.

Compounds and methods for antiviral treatment

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions. 

Gamma secretase modulators

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes

Growing community of inventors

Seabrook Island, SC, United States of America

Malcolm Maccoss